Recurrent / Unprovoked VTE & Thrombophilia

📋 Key Information Summary

📋

Unprovoked VTE is defined as venous thromboembolism occurring without a major transient provoking factor (surgery, trauma, plaster cast, hospitalisation >3 days) — distinguishing it from provoked VTE is critical as it dictates duration of anticoagulation.
Approximately 30–50% of first VTE events in Australia are classified as unprovoked, with recurrence rates of 10% at 1 year and 30% at 5 years if anticoagulation is stopped after 3–6 months.
Individualised risk assessment using validated tools (Vienna Prediction Model, DASH score, HERDOO2 for women) guides the decision to stop versus continue anticoagulation beyond initial treatment.
Extended anticoagulation (beyond 3–6 months) is recommended for most patients with unprovoked VTE if bleeding risk is low-to-moderate and the patient consents; a reduced-dose DOAC (rivaroxaban 10 mg or apixaban 2.5 mg BD) offers a favourable efficacy-to-bleeding ratio for secondary prevention.
Thrombophilia testing is NOT routinely recommended for all unprovoked VTE; it should be performed selectively — particularly in young patients (<50 years), those with a strong family history, or unusual site thromboses (cerebral venous, splanchnic, portal).
Never perform thrombophilia testing during the acute VTE event or while the patient is on anticoagulation — warfarin falsely lowers Protein C and S; DOACs interfere with lupus anticoagulant assays; test ≥2 weeks after stopping anticoagulation where clinically indicated.
A positive thrombophilia panel does not automatically mandate lifelong anticoagulation — clinical context, bleeding risk, and patient preference must be integrated; isolated Factor V Leiden heterozygosity has modest recurrence risk.
Antiphospholipid syndrome (APS) is a special case: triple-positive APS with prior unprovoked VTE warrants long-term warfarin (INR 2–3), not DOACs, based on TRAPS trial data.
Refer to haematology for complex decisions about lifelong anticoagulation, positive or ambiguous thrombophilia results, recurrent VTE despite adequate therapy, unusual site thrombosis, and anticoagulation in high-bleeding-risk patients.
Aboriginal and Torres Strait Islander Australians experience higher VTE incidence, later presentation, and greater barriers to INR monitoring and specialist access — culturally safe shared decision-making and remote monitoring pathways are essential.
All patients on extended anticoagulation require regular reassessment (at least annually) of thrombotic risk, bleeding risk, renal function, medication adherence, and patient preference — use the HAS-BLED score to quantify bleeding risk.
Direct oral anticoagulants (DOACs) are first-line for most patients with unprovoked VTE; rivaroxaban and apixaban do not require bridging with parenteral anticoagulation and have predictable pharmacokinetics, but renal and hepatic function must be assessed before initiation.

Introduction & Australian Epidemiology

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), affects an estimated 15,000–20,000 Australians annually. Around one-third to one-half of these events occur without an identifiable major transient provoking factor — classified as unprovoked (idiopathic) VTE. The distinction between provoked and unprovoked VTE is one of the most consequential in thrombosis medicine, as it directly determines whether a patient is treated with a finite course of anticoagulation (typically 3–6 months) or considered for extended/indefinite therapy.

The annual incidence of VTE in Australia is approximately 83 per 100,000 population, with incidence rising sharply with age — from ~10 per 100,000 in those aged 20–29 to >500 per 100,000 in those aged ≥80 years. Males have a slightly higher incidence than females, and the in-hospital mortality for acute PE remains 8–10%, rising to 25–30% for massive PE with haemodynamic instability.

Unprovoked VTE carries a recurrence rate of approximately 10% at 1 year and 30% at 5 years if anticoagulation is discontinued after the initial 3–6 month treatment period. This recurrence risk is the central driver of extended anticoagulation decisions. The case-fatality rate of recurrent VTE is estimated at 3.6%, while major bleeding on anticoagulation carries a case-fatality rate of approximately 9–11%, underscoring the importance of individualised risk–benefit assessment.

⚠️

Clinical imperative: Misclassifying a provoked VTE as unprovoked (or vice versa) may lead to either unnecessary lifelong anticoagulation or premature cessation of therapy with potentially fatal recurrence. A careful, structured provocation assessment is mandatory at the time of initial VTE diagnosis.

This guideline addresses the Australian clinical approach to unprovoked VTE, the role of thrombophilia testing, the decision framework for extended anticoagulation, and the indications for specialist haematology referral.

Defining Unprovoked VTE

The classification of VTE as provoked or unprovoked is based on the presence or absence of identifiable risk factors at the time of the event. This distinction is fundamental — it guides anticoagulation duration, the role of thrombophilia testing, and long-term management strategy.

Major Transient (Surgical) Provoking Factors

VTE is considered provoked if it occurs within the timeframe associated with a major transient risk factor. These factors carry the highest attributable risk:

Surgery requiring general or regional anaesthesia lasting >30 minutes (within 6 weeks)
Lower-limb trauma or fracture requiring immobilisation (within 6 weeks)
Hospitalisation with acute medical illness for ≥3 days (within 6 weeks)
Plaster cast or significant immobilisation of a lower limb (within 6 weeks)

Minor / Persistent Provoking Factors

These factors increase VTE risk but are considered minor — VTE occurring in the context of these alone may still be classified as unprovoked by some scoring systems, and clinical judgement is required:

Oestrogen-containing therapy (combined oral contraceptive pill, HRT) — within 6 weeks of starting
Pregnancy or the puerperium (within 6 weeks postpartum)
Long-haul travel (>4 hours) within 4 weeks
Minor lower-limb surgery or injury not requiring immobilisation
Active malignancy (note: cancer-associated VTE is often managed as a separate pathway)

ℹ️

Consensus approach in Australia: Most Australian haematologists classify VTE as provoked only if a major transient risk factor is present. VTE occurring with minor risk factors alone (e.g., the oral contraceptive pill, long-haul travel) is generally treated as unprovoked for the purposes of anticoagulation duration decisions.

Unprovoked VTE — Operational Definition

VTE is classified as unprovoked when:

No major transient provoking factor is identified within 6 weeks preceding the event, AND
No active malignancy is present (or diagnosed within 6 months), AND
No major persistent risk factor is present (e.g., antiphospholipid syndrome, known severe thrombophilia)

Factors Influencing the Unprovoked Classification

Factor	Consideration	Impact on Classification
Age at first VTE	Younger age (<50 years) without provocation raises suspicion for inherited thrombophilia	Strengthens case for unprovoked and thrombophilia testing
Family history	First-degree relative with VTE before age 50	Supports inherited predisposition; consider thrombophilia screen
Obesity (BMI ≥30)	Persistent risk factor increasing baseline VTE risk 2–3×; does not typically reclassify to provoked	Considered a background risk; VTE still classified as unprovoked
Bleeding risk	Age ≥65, prior GI bleed, renal impairment, thrombocytopaenia, concurrent antiplatelet therapy	Does not affect provocation status but critical for anticoagulation duration decisions
Unusual site VTE	Cerebral venous sinus, portal, mesenteric, hepatic, renal vein thrombosis	Raises suspicion for underlying thrombophilia, myeloproliferative neoplasm, or paroxysmal nocturnal haemoglobinuria

🚨

Common pitfall: Stopping anticoagulation at 3 months in an unprovoked VTE because it was classified as "minor-provoked" (e.g., by the oral contraceptive pill) without considering that most guidelines treat this as unprovoked. Always confirm the provocation classification with the treating haematologist or use a validated decision tool.

Risk Stratification & Prediction Scores

Several validated clinical prediction scores assist in estimating the risk of VTE recurrence after unprovoked first VTE, helping to stratify patients into those who may safely discontinue anticoagulation versus those who benefit from extended therapy.

Vienna Prediction Model

The most validated score, using three variables assessed after completing initial anticoagulation:

Sex — male sex confers higher recurrence risk
D-dimer level measured 3 weeks after stopping anticoagulation — elevated D-dimer (>500 µg/L) increases recurrence risk 2–3×
Location of index VTE — PE ± DVT vs isolated DVT

The model generates a continuous probability of recurrence at 12, 24, and 60 months, enabling personalised shared decision-making.

DASH Score (for Recurrence after Unprovoked VTE)

Variable	Points
D-dimer abnormal after stopping anticoagulation	+2
Age ≤50 years	+1
Sex — male	+1
Hormone use (VTE on OCP/HRT) — reclassified as provoked	−2

Score ≤1: Low recurrence risk (~3% per year) — consider stopping anticoagulation
Score ≥2: High recurrence risk (~10% per year) — favour extended anticoagulation

HERDOO2 Score (Women Only)

Specifically developed to identify low-risk women who may safely discontinue anticoagulation after unprovoked VTE:

Hyperpigmentation, oedema, or redness of either leg
Elevated D-dimer (>250 µg/L while on anticoagulation)
Residual venous obstruction on ultrasound (>4 mm)
DO2: Obesity (BMI ≥30) and age ≥65
0–1 risk factors: Low risk — safe to stop (recurrence ~3% per year)
≥2 risk factors: High risk — extended anticoagulation recommended

✅

Australian practice point: The Vienna Prediction Model and DASH score are the most commonly used tools in Australian haematology practice. A post-anticoagulation D-dimer (measured 1–3 weeks after stopping the DOAC or on the day of stopping warfarin, with result reviewed at 3–4 weeks) is the single most useful biomarker for recurrence risk stratification.

Investigations & Thrombophilia Testing

Routine VTE Investigations

All patients presenting with suspected VTE should undergo standard diagnostic workup as per Australian guidelines (D-dimer, compression ultrasound for DVT, CT pulmonary angiography for PE). Beyond acute diagnosis, the following investigations are relevant for the long-term workup of unprovoked VTE:

Essential

Complete blood count, coagulation studies

Baseline FBC, PT/INR, aPTT, fibrinogen — screen for polycythaemia, thrombocytopaenia, coagulopathy. Available at all Australian pathology providers. MBS item 65070.

Essential

Renal function (eGFR)

Crucial before DOAC initiation — apixaban and rivaroxaban require dose adjustment if eGFR <30 mL/min; dabigatran contraindicated if eGFR <30 mL/min. MBS item 66500.

Essential

Liver function tests

Baseline hepatic assessment; DOACs are contraindicated in severe hepatic impairment (Child-Pugh C). MBS item 66512.

Available

D-dimer (post-anticoagulation)

Measure 1–3 weeks after stopping anticoagulation (or on last day of warfarin). Elevated D-dimer (>500 µg/L) is the strongest single predictor of VTE recurrence. Available at all Australian pathology providers. MBS item 65123.

Available

Age-appropriate cancer screening

History, examination, age-appropriate cancer screening (bowel, breast, cervical, prostate) — occult malignancy accounts for ~5–8% of apparently unprovoked VTE. Do not routinely perform extensive CT screening unless clinically indicated.

Thrombophilia Testing — Principles

🚨

CRITICAL — Do NOT test during the acute event or while on anticoagulation. Acute VTE causes consumption of antithrombin, Protein C, and Protein S, leading to falsely low levels. Warfarin reduces Protein C and S, and DOACs interfere with lupus anticoagulant and chromogenic assays. Testing must be deferred until ≥2 weeks after stopping anticoagulation, or performed on warfarin with appropriate interpretation (only Factor V Leiden, prothrombin gene mutation, and antiphospholipid antibodies by ELISA are reliable on warfarin).

When to Test

Thrombophilia testing is indicated selectively, not as a routine screen. Australian haematology consensus supports testing in:

Young patients (<50 years) with unprovoked VTE
Strong family history of VTE (≥1 first-degree relative with VTE before age 50)
Unusual site thrombosis (cerebral venous sinus, portal/hepatic, mesenteric, renal vein)
Recurrent VTE
Warfarin-induced skin necrosis or heparin-induced thrombocytopaenia (specialised testing)
Neonatal purpura fulminans (Protein C or S deficiency)

When NOT to Test

Routine testing in all provoked VTE patients — low yield, does not change management
During the acute VTE event (consumption artifacts)
While on anticoagulation (interference with functional assays; if testing is unavoidable, genetic tests only — Factor V Leiden, prothrombin mutation)
In patients aged >50 with clearly provoked VTE and no family history

Thrombophilia Panel — Components

Test	Method	Prevalence in VTE	Key Notes
Factor V Leiden mutation	PCR (genetic) — reliable on anticoagulation	20–25% of unprovoked VTE	Heterozygous: 3–8× risk. Homozygous: 50–80× risk. Most common inherited thrombophilia. Prevalence ~5% in Australian Caucasians.
Prothrombin G20210A mutation	PCR (genetic) — reliable on anticoagulation	6–8% of unprovoked VTE	Heterozygous: 2–5× risk. Prevalence ~2% in Australian Caucasians.
Antithrombin III deficiency	Chromogenic activity assay — must be off anticoagulation	1–3% of unprovoked VTE	Strongest risk (10–50×). Rare but high-risk. Acute VTE and heparin falsely lower levels.
Protein C deficiency	Chromogenic or clotting assay — must be off warfarin ≥2 weeks	3–5% of unprovoked VTE	Warfarin falsely lowers Protein C. Recheck off treatment. Heterozygous: 7–10× risk.
Protein S deficiency	Free Protein S antigen + activity — must be off warfarin ≥2 weeks	1–5% of unprovoked VTE	Warfarin and OCP lower Protein S. Pregnancy lowers Protein S. Confirm with repeat testing.
Antiphospholipid antibodies (aPL)	Lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM	5–15% of unprovoked VTE	Test off anticoagulation (LA unreliable on DOACs/warfarin). Must be positive on ≥2 occasions ≥12 weeks apart for APS diagnosis. ELISA-based aCL and anti-β2GPI reliable on warfarin.
Elevated Factor VIII	Clotting activity assay	Common (acute phase reactant)	Elevated levels (>150 IU/dL) associated with increased VTE risk. Non-specific — rises with acute inflammation, pregnancy, OCP. Interpret cautiously.
Elevated homocysteine	Plasma homocysteine, MTHFR genotype	Variable	MTHFR C677T homozygosity common but NOT a significant independent VTE risk factor. Folate/B12 deficiency correctable. No longer routinely recommended.

⚠️

Important: A positive thrombophilia test result does NOT automatically mean lifelong anticoagulation. For example, heterozygous Factor V Leiden alone increases recurrence risk modestly (OR ~1.4 after adjusting for other factors). The decision to extend anticoagulation must integrate the thrombophilia result with clinical recurrence risk, bleeding risk, and patient preference. Coordinate all testing with haematology.

Australian Pathology Considerations

Genetic tests (Factor V Leiden, prothrombin mutation) are available through major Australian pathology providers (Sullivan Nicolaides, Douglass Hanly Moir, Melbourne Pathology, Clinpath) and are bulk-billed with a valid Medicare referral.
Functional thrombophilia assays (antithrombin, Protein C, Protein S) require specialised coagulation laboratories — most are available through capital city-based referral laboratories.
Antiphospholipid antibody testing (lupus anticoagulant) requires samples to be processed within 4 hours — contact the laboratory prior to collection.
MBS items for thrombophilia genetic testing: 73294 (Factor V Leiden), 73296 (prothrombin mutation). Functional assays are billed under coagulation MBS items.

Extended Anticoagulation

The decision to continue anticoagulation beyond the initial 3–6 months after unprovoked VTE is one of the most common clinical dilemmas in Australian haematology and general practice. The decision must balance the ongoing risk of VTE recurrence against the risk of major bleeding.

Decision Framework

1

Classify the VTE

Confirm unprovoked status. Re-evaluate for occult malignancy, oestrogen use, and immobilisation. Document provocation clearly in the clinical record.

2

Assess recurrence risk

Use the Vienna Prediction Model, DASH score, or HERDOO2 (for women). Consider thrombophilia results if tested. Male sex and elevated post-treatment D-dimer are the strongest independent predictors.

3

Assess bleeding risk

Apply HAS-BLED score. Consider age ≥65, prior major bleeding, eGFR <30–50, thrombocytopaenia (<100 × 10⁹/L), concurrent antiplatelet therapy, liver disease, alcohol excess.

4

Shared decision-making

Discuss absolute risks and benefits with the patient. Present recurrence risk (~10%/yr if stopped vs ~4%/yr on extended therapy), major bleeding risk (~1–3%/yr on anticoagulation), and the patient's values and preferences.

5

Choose agent and dose

If extending: reduced-dose DOAC (rivaroxaban 10 mg OD or apixaban 2.5 mg BD) is preferred for most patients. Full-dose DOAC or warfarin for high-risk patients (APS, antithrombin deficiency, recurrent VTE on treatment).

Recommendations by Risk Profile

Low Recurrence Risk

Consider Stopping Anticoagulation

DASH ≤1, HERDOO2 0–1 (women), normal post-treatment D-dimer, female sex, isolated provoked by OCP/HRT. Recurrence risk ~3%/yr. Reasonable to stop after 3–6 months with D-dimer monitoring.

Setting: GP-led with haematology input if needed

Moderate Recurrence Risk

Extended Anticoagulation — Reduced-Dose DOAC

DASH 2, elevated post-treatment D-dimer, male sex with first unprovoked VTE. Recurrence risk ~7–10%/yr. Extended reduced-dose DOAC (rivaroxaban 10 mg OD or apixaban 2.5 mg BD) recommended if bleeding risk acceptable. Annual reassessment.

Setting: Shared care GP–haematologist

High Recurrence Risk

Indefinite Full-Dose Anticoagulation

Recurrent unprovoked VTE, antiphospholipid syndrome (triple-positive), severe thrombophilia (antithrombin deficiency), unusual site VTE with thrombophilia, or recurrent VTE despite anticoagulation. Consider full-dose DOAC or warfarin (for APS, INR 2–3).

Setting: Specialist haematologist-led

Anticoagulant Options for Extended Therapy

💊

Rivaroxaban (reduced dose)

Xarelto® · Direct Factor Xa inhibitor

Adult dose (secondary prevention) 10 mg PO OD (after completing ≥6 months of initial anticoagulation)

Standard treatment dose 15 mg PO BD × 21 days, then 20 mg PO OD (with food)

Renal adjustment Avoid if eGFR <15 mL/min. Caution if eGFR 15–30. No dose adjustment for 10 mg dose at eGFR 30–50.

Hepatic adjustment Contraindicated in Child-Pugh B or C hepatic impairment

PBS status Authority Required (STREAMLINED 5173)

💊

Apixaban (reduced dose)

Eliquis® · Direct Factor Xa inhibitor

Adult dose (secondary prevention) 2.5 mg PO BD (after completing ≥6 months of initial anticoagulation)

Standard treatment dose 10 mg PO BD × 7 days, then 5 mg PO BD

Renal adjustment For 2.5 mg BD dose: no adjustment unless ≥2 of (age ≥80, weight ≤60 kg, Cr ≥133 µmol/L) — use with caution. Avoid if eGFR <15 mL/min.

Hepatic adjustment Contraindicated in severe hepatic impairment

PBS status Authority Required (STREAMLINED 5171)

💊

Dabigatran

Pradaxa® · Direct thrombin inhibitor

Adult dose 150 mg PO BD (after ≥5 days of parenteral anticoagulation for initial treatment; for extended prevention, 150 mg BD or 110 mg BD in elderly/bleeding risk)

Renal adjustment Contraindicated if eGFR <30 mL/min. Avoid 150 mg dose if eGFR 30–50 with high bleeding risk. Use 110 mg BD.

Note Requires initial parenteral anticoagulation before switching. Idarucizumab (Praxbind®) is the specific reversal agent.

PBS status Authority Required (STREAMLINED 5172)

💊

Warfarin

Coumadin® / Marevan® · Vitamin K antagonist

Adult dose Individually titrated to INR 2.0–3.0 (target 2.5). Typical maintenance 2–5 mg PO daily.

Indications for warfarin over DOACs Antiphospholipid syndrome (triple-positive), mechanical heart valves, severe renal impairment (eGFR <15), patient preference, cost considerations

Renal adjustment No renal dose adjustment (hepatically metabolised) — preferred in severe CKD

PBS status ✔ PBS General Benefit

💊

Enoxaparin

Clexane® · Low-molecular-weight heparin

Adult dose (extended VTE treatment) 1.5 mg/kg SC OD or 1 mg/kg SC BD (treatment); 40 mg SC OD (prophylaxis)

Indications for extended use Pregnancy (DOACs contraindicated), cancer-associated VTE, patients unable to take oral medications, bridging before warfarin

Renal adjustment Reduce dose if eGFR <30 mL/min (1 mg/kg SC OD or unfractionated heparin preferred)

PBS status ✔ PBS General Benefit

⚠️

APS and DOACs: The TRAPS trial (2018) demonstrated that rivaroxaban was inferior to warfarin in triple-positive antiphospholipid syndrome, with increased thrombotic events. Warfarin (INR 2–3) remains the standard of care for APS with prior VTE. DOACs should not be used in triple-positive APS. For single- or double-positive APS, haematology guidance is recommended.

DOAC Dose-Reduction Criteria Summary

DOAC	Treatment Dose	Extended / Secondary Prevention Dose	Dose-Reduction Criteria
Rivaroxaban	15 mg BD × 21 days → 20 mg OD	10 mg OD	eGFR 15–30: consider 15 mg OD (treatment); no adjustment for 10 mg
Apixaban	10 mg BD × 7 days → 5 mg BD	2.5 mg BD	≥2 of: age ≥80, weight ≤60 kg, Cr ≥133 µmol/L
Dabigatran	150 mg BD (after parenteral lead-in)	150 mg BD (or 110 mg BD)	eGFR 30–50, age ≥80, concurrent P-gp inhibitors, high bleeding risk → 110 mg BD
Edoxaban	60 mg OD (after ≥5 days parenteral anticoagulation)	Not PBS-listed for extended VTE prevention in Australia	Reduce to 30 mg OD if eGFR 15–50, weight ≤60 kg, or concurrent P-gp inhibitors

Monitoring on Extended Anticoagulation

All patients on extended anticoagulation require structured, longitudinal monitoring to detect complications early, ensure therapeutic adequacy, and facilitate shared decision-making about ongoing therapy.

Monitoring Schedule

Baseline (at initiation)

FBC, renal function (eGFR), LFTs, coagulation screen, weight, blood pressure. Document indication, target INR (warfarin), and planned review date. Assess bleeding risk with HAS-BLED. Provide patient information on signs of bleeding and thrombosis.

1 month

Assess adherence, tolerance, bruising, bleeding, and drug interactions. Renal function if elderly or CKD. INR check if on warfarin.

3 months

Clinical review. Renal function. TTR (time in therapeutic range) assessment if on warfarin (target >65%). FBC to detect occult bleeding (iron deficiency anaemia).

6 months

Comprehensive review — recurrence risk reassessment, bleeding events, renal function, LFTs, adherence, ongoing indication confirmed. D-dimer if considering stopping anticoagulation.

Annually (ongoing)

Annual specialist or shared-care review. Repeat bleeding risk assessment (HAS-BLED). Renal function (eGFR), FBC, LFTs. Screen for new drug interactions. Discuss ongoing patient preference for continued anticoagulation vs risk-managed cessation.

Warfarin-Specific Monitoring

ℹ️

INR Monitoring Frequency: When stable (TTR >65%, consecutive INRs in range), INR testing can be extended to every 4–6 weeks. Patients in remote/regional areas may benefit from point-of-care INR testing (CoaguChek®) through GP clinics or community pharmacies participating in the Australian INR Monitoring Program. Medicare rebates apply for INR self-monitoring training (MBS item 11505).

DOAC-Specific Monitoring

Routine coagulation monitoring (INR, aPTT) is NOT required for DOACs — these tests are unreliable for measuring DOAC anticoagulant effect.
If DOAC level measurement is needed (e.g., before emergency surgery, overdose, major bleeding): anti-Xa levels for rivaroxaban/apixaban; dilute thrombin time or ecarin clotting time for dabigatran.
Renal function monitoring: Every 6 months if eGFR 30–60; every 3 months if eGFR <30. Dose adjustment or change of agent if renal function declines.
FBC annually: To detect iron deficiency anaemia (occult GI bleeding) or thrombocytopaenia.
Annual review of concurrent medications — DOACs interact with P-glycoprotein and CYP3A4 inhibitors/inducers (azole antifungals, rifampicin, carbamazepine, phenytoin, St John's wort).

D-Dimer Monitoring for Anticoagulation Cessation

If a shared decision is made to trial stopping anticoagulation:

Check D-dimer 1–3 weeks after stopping the anticoagulant (off treatment).
If D-dimer is elevated (>500 µg/L) — recurrence risk increases 2–3×; strongly consider restarting anticoagulation.
If D-dimer is normal (<500 µg/L) — recurrence risk is lower but not negligible; repeat D-dimer at 1, 3, 6, and 12 months, then annually.
Any recurrent D-dimer elevation warrants re-evaluation and likely resumption of anticoagulation.

Special Populations

🤰

Pregnancy & Breastfeeding

DOACs (rivaroxaban, apixaban, dabigatran) Contraindicated in pregnancy — teratogenic (rivaroxaban), limited safety data. Must be stopped and transitioned to LMWH before conception or as soon as pregnancy is confirmed.

Enoxaparin (Clexane®) Anticoagulant of choice in pregnancy. Does not cross the placenta. Dose: 1 mg/kg SC BD (treatment) — weight-adjusted, monitored with anti-Xa levels (target 0.5–1.0 IU/mL at 4 hours post-dose). Switch to UFH at 36 weeks or 24 hours before planned delivery.

Warfarin Teratogenic in first trimester (warfarin embryopathy). Can be used in second/third trimester for mechanical valves or APS under specialist guidance. Contraindicated near term (fetal haemorrhage).

Postpartum LMWH or warfarin can be used postpartum. DOACs are excreted in breast milk — dabigatran is preferred if DOAC is required post-breastfeeding (lowest transfer). Rivaroxaban and apixaban: avoid during breastfeeding.

👶

Paediatrics

Unprovoked VTE in children Rare — always investigate for underlying malignancy, autoimmune disease, or central venous catheter. Thrombophilia testing is more readily indicated in paediatric unprovoked VTE.

Anticoagulation LMWH (enoxaparin) is first-line for children. Warfarin for longer-term therapy. DOACs are not TGA-approved for paediatric VTE treatment in Australia. Refer to paediatric haematology.

👴

Elderly (≥65 years)

Bleeding risk Substantially increased — HAS-BLED score should be applied. Annual major bleeding risk on anticoagulation rises from ~1–2% in younger patients to 4–6% in those ≥75 years. Falls risk alone is not a contraindication to anticoagulation.

DOAC preference Apixaban has the most favourable bleeding profile in the elderly based on AMPLIFY and ARISTOTLE data. Reduced-dose apixaban (2.5 mg BD) or rivaroxaban (10 mg OD) for extended prevention. Avoid dabigatran if eGFR <30.

Polypharmacy Review all concurrent medications for DOAC interactions. Concurrent aspirin/NSAIDs significantly increase bleeding risk. Deprescribe unnecessary antiplatelet agents.

🫘

Renal Impairment

eGFR 30–50 mL/min DOACs can be used with dose reduction. Rivaroxaban 10 mg OD (secondary prevention) requires no adjustment. Monitor renal function every 3 months.

eGFR <30 mL/min Warfarin is preferred. Enoxaparin at reduced dose (1 mg/kg SC OD). Dabigatran is contraindicated. Rivaroxaban and apixaban can be used with caution. Refer to nephrology and haematology.

Dialysis Warfarin is the standard anticoagulant. Limited DOAC data in dialysis. Specialist management required.

🫁

Hepatic Impairment

Child-Pugh A DOACs can generally be used with caution. Monitor LFTs regularly. Rivaroxaban: use with caution.

Child-Pugh B & C DOACs are contraindicated. Warfarin is preferred but requires careful INR monitoring as liver disease impairs synthesis of coagulation factors and may cause unpredictable INR response. Enoxaparin use with caution. Refer to hepatology and haematology.

🛡️

Immunocompromised

HIV Increased VTE risk (2–10×). Consider antiphospholipid antibodies, Protein S deficiency (HIV-associated). Check for drug interactions with antiretrovirals — protease inhibitors (ritonavir) inhibit CYP3A4 and P-gp, increasing DOAC levels; avoid rivaroxaban with strong CYP3A4 inhibitors. Apixaban or dabigatran preferred.

Active malignancy Cancer-associated VTE is managed differently — LMWH or edoxaban/rivaroxaban preferred (CARAVAGGIO, SELECT-D trials). Refer to oncology and haematology for cancer-associated VTE pathways.

When to Refer to Haematology

While many aspects of VTE management can be confidently managed in primary care, several clinical scenarios in unprovoked VTE warrant specialist haematology referral. The following table summarises referral indications and urgency.

Referral Indications

Indication	Urgency	Rationale
First unprovoked VTE — decision about anticoagulation duration	Semi-urgent (within 4–6 weeks)	Complex risk stratification; patient education about extended therapy; D-dimer-guided decision-making.
Recurrent VTE despite adequate anticoagulation	Urgent (within 1–2 weeks)	Consider treatment failure, heparin-induced thrombocytopaenia, antiphospholipid syndrome, malignancy, non-adherence, or incorrect VTE diagnosis.
Positive or ambiguous thrombophilia panel	Semi-urgent	Interpretation of results, confirmation testing (repeat functional assays off treatment), counselling about implications for patient and family, anticoagulation duration decision.
Suspected antiphospholipid syndrome	Semi-urgent	Requires confirmation with repeat testing ≥12 weeks apart, classification as single/double/triple positive, and warfarin (not DOAC) for triple-positive APS.
Unusual site VTE (cerebral, portal, mesenteric, renal)	Urgent	Higher prevalence of underlying thrombophilia, myeloproliferative neoplasm (JAK2 mutation), paroxysmal nocturnal haemoglobinuria. Multidisciplinary approach required.
Patient with high bleeding risk requiring anticoagulation	Semi-urgent	Shared decision-making about risk–benefit; consideration of reduced-dose DOAC, left atrial appendage closure, or alternative strategies.
Lifelong anticoagulation discussion — young patient	Routine (within 8–12 weeks)	Long-term implications for contraception, pregnancy planning, travel, sport, surgical procedures, insurance, and psychological wellbeing.
VTE in pregnancy or planning pregnancy	Urgent	Transition from DOACs to LMWH; management of APS in pregnancy; thromboprophylaxis planning for delivery; postnatal anticoagulation strategy.
DOAC failure or intolerance	Semi-urgent	Consider switch to alternative DOAC, warfarin, or LMWH. Investigate cause of failure (non-adherence, drug interaction, incorrect dose, resistance).

ℹ️

Australian referral pathways: Haematology referrals can be directed to hospital-based haematology outpatient clinics (public) or private haematologists. In regional and remote areas, the Royal Flying Doctor Service (RFDS) and telehealth haematology consultations (available through many state health networks) provide specialist access. Patients in rural/remote Queensland can access the QTelehealth haematology service. Wait times for non-urgent haematology outpatient appointments in major centres are typically 4–12 weeks.

Red Flags Requiring Immediate Assessment

🚨

Recurrent PE with haemodynamic instability — immediate escalation to ED / critical care
Major bleeding on anticoagulation — activate major haemorrhage protocol; use reversal agents (idarucizumab for dabigatran; andexanet alfa for rivaroxaban/apixaban; vitamin K + PCC for warfarin)
Superior vena cava obstruction — urgent CT and haematology/oncology assessment
Suspected heparin-induced thrombocytopaenia (HIT) — stop all heparin, initiate alternative anticoagulation (argatroban or fondaparinux), urgent haematology referral

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a higher burden of cardiovascular disease, including VTE, compared with non-Indigenous Australians. Access to specialist haematology services, INR monitoring, and culturally safe care pathways remains a significant challenge, particularly in remote communities. The following considerations should be integrated into all VTE management decisions for Indigenous patients.

VTE incidence & outcomes

Aboriginal and Torres Strait Islander Australians have a higher incidence of VTE and present at a younger age with more comorbidities (diabetes, renal disease, obesity, rheumatic heart disease). Hospitalisation rates for VTE are 1.5–2× higher than non-Indigenous Australians (AIHW data). VTE-related mortality is also elevated, partly reflecting later presentation and comorbidity burden.

Remote access

Specialist haematology services are concentrated in metropolitan and large regional centres. Patients in remote NT, WA, QLD, and SA communities may be >500 km from the nearest haematologist. Telehealth, RFDS-supported consultations, and outreach clinics (e.g., NT haematology outreach) are essential. Point-of-care INR testing (CoaguChek®) should be available in all remote clinics managing patients on warfarin.

INR monitoring challenges

Warfarin requires regular INR monitoring, which is difficult in remote settings with limited pathology collection services. DOACs may be preferred in eligible patients as they do not require INR monitoring, provided renal function can be monitored and the medication is affordable and accessible through community stores or remote pharmacies. Aboriginal Health Workers trained in INR monitoring improve continuity of care.

Thrombophilia testing

Thrombophilia testing requires blood collection with specific handling (lupus anticoagulant samples must be processed within 4 hours). In remote settings, this often requires coordination with the regional pathology service and may involve air-freighting samples. Genetic tests (Factor V Leiden, prothrombin mutation) are more practical as they use stable samples. Testing should still be offered when indicated — do not withhold testing solely based on remoteness.

Medication access & cost

DOACs are PBS-listed but require Authority prescriptions. In remote communities, medication supply may be intermittent. Warfarin and enoxaparin are generally well-supplied through remote area health services. Ensure prescriptions are dispensed with adequate supply for community store closures or wet-season access limitations. Concession card holders have reduced PBS co-payments.

Cultural safety

VTE management discussions should involve family and community where the patient wishes. Use Aboriginal Health Practitioners and Liaison Officers as cultural brokers. Recognise that concepts of "lifelong medication" may require careful explanation and culturally appropriate health literacy resources. The RACGP's guide to providing care for Aboriginal and Torres Strait Islander people and AHMAC cultural competency frameworks should underpin all consultations. Preferred terminology: "Aboriginal and Torres Strait Islander" or the specific nation/community name, as preferred by the individual.

Rheumatic heart disease (RHD) overlap

RHD is significantly more prevalent in Aboriginal and Torres Strait Islander Australians, particularly in the NT and remote QLD. Patients with RHD and atrial fibrillation may already be on anticoagulation (warfarin). Unprovoked VTE in this context requires careful haematology input to manage dual indications and bleeding risk. The RHDAustralia register (End RHD CRC) facilitates coordinated care.

Chronic kidney disease (CKD)

CKD prevalence is 2–3× higher in Aboriginal and Torres Strait Islander Australians. Renal function must be closely monitored in all patients on DOACs. Warfarin may be preferred in patients with eGFR <30. Coordinate with renal services for patients on dialysis.

💚

Best practice: Engage Aboriginal Health Workers and Practitioners in VTE education, INR monitoring (where trained), medication adherence support, and DVT/PE symptom recognition. Support community-led health promotion around VTE risk factors (immobilisation during long drives, post-surgical care after medical evacuations). Partner with local Aboriginal Community Controlled Health Organisations (ACCHOs) for shared-care pathways.

📚 References

1. Kearon C, Ageno W, Cannegieter SC, et al. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480–1483.
2. Kyrle PA, Kammer M, Eichinger S. Prediction of recurrent venous thromboembolism by the Vienna Prediction Model. N Engl J Med. 2022;386(18):1734–1743.
3. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost. 2012;10(6):1019–1025.
4. Rodger MA, Le Gal G, Anderson DR, et al. Validating the HERDOO2 rule to identify women with unprovoked VTE who can safely stop anticoagulants. CMAJ. 2017;189(19):E681–E687.
5. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism (AMPLIFY-EXT). N Engl J Med. 2013;368(8):699–708.
6. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism (EINSTEIN-CHOICE). N Engl J Med. 2017;376(13):1211–1222.
7. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood. 2018;132(13):1365–1371.
8. Tran HA, Gibbs H, Merriman E, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust. 2019;210(5):227–235.
9. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209–220.
10. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease in Aboriginal and Torres Strait Islander people. AIHW; 2023. Canberra: AIHW.
11. National Health and Medical Research Council (NHMRC). Clinical practice guideline for the prevention of venous thromboembolism in patients admitted to Australian hospitals. NHMRC; 2009 (updated 2018). Melbourne: NHMRC.
12. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2019;3(24):4028–4037.
13. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543–603.
14. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
15. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154–164.
16. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 9th ed. Melbourne: RACGP; 2018.